Erratum: Withdrawal: Sulforaphane attenuates muscle inflammation in dystrophin-deficient mdx mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-κB signaling pathway (Journal of Biological Chemistry (2015) 290(29) (17784–17795), (S0021925820423774), (10.1074/jbc.M115.655019));Sulforaphane attenuates muscle inflammation in dystrophin-deficient mdx mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-κB signaling pathway

Journal of Biological Chemistry

Volumn 290, Issue 29, 2015, Pages 17784-17795

  Sun, Cheng Cao ^a   Li, Shu Jun ^a   Yang, Cui Li ^a   Xue, Rui Lin ^a   Xi, Yong Yong ^a   Wang, Liang ^a   Zhao, Qian Long ^b   Li, De Jia ^a  

^a WUHAN UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALS; PATHOLOGY; SIGNALING;

DYSTROPHIN; RELATED FACTORS; SIGNALLING PATHWAYS; SULFORAPHANE; THERAPEUTIC TARGETS;

MUSCLE;

CD45 ANTIGEN; DYSTROPHIN; HEME OXYGENASE 1; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; HMOX1 PROTEIN, MOUSE; ISOTHIOCYANIC ACID DERIVATIVE; MEMBRANE PROTEIN; SULFORAFAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME PHOSPHORYLATION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; MUSCULAR DYSTROPHY; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT DURATION; AGONISTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE DELETION; GENETICS; IMMUNOLOGY; INFLAMMATION; MUSCULAR DYSTROPHY, DUCHENNE; OXIDATIVE STRESS; ULTRASTRUCTURE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DYSTROPHIN; GENE DELETION; HEME OXYGENASE-1; INFLAMMATION; ISOTHIOCYANATES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84937501226     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1016/j.jbc.2023.105434     Document Type: Erratum

References (52)

1. Hoffman, E. P., and Brown, R. H., Jr., and Kunkel, L. M. (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928
2. Govoni, A., Magri, F., Brajkovic, S., Zanetta, C., Faravelli, I., Corti, S., Bresolin, N., and Comi, G. P. (2013) Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell. Mol. Life Sci. 70, 4585-4602
3. Deconinck, N., and Dan, B. (2007) Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36, 1-7
4. Campbell, K. P. (1995) Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-679
5. Tidball, J. G., and Wehling-Henricks, M. (2005) Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. Curr. Opin Rheumatol. 17, 707-713
6. Tidball, J. G., and Wehling-Henricks, M. (2004) Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr. Res. 56, 831-841
7. Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., Poysky, J., Shapiro, F., Tomezsko, J., Constantin, C., and DMD Care Considerations Working Group (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77-93
8. Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., and Tidball, J. G. (2009) Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 18, 482-496
9. Bhatnagar, S., and Kumar, A. (2010) Therapeutic targeting of signaling pathways in muscular dystrophy. J. Mol. Med. 88, 155-166
10. Lee, J. H., Khor, T. O., Shu, L., Su, Z. Y., Fuentes, F., and Kong, A. N. (2013) Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol. Ther. 137, 153-171
11. Osburn, W. O., Karim, B., Dolan, P. M., Liu, G., Yamamoto, M., Huso, D. L., and Kensler, T. W. (2007) Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int. J. Cancer 121, 1883-1891
12. Rangasamy, T., Guo, J., Mitzner, W. A., Roman, J., Singh, A., Fryer, A. D., Yamamoto, M., Kensler, T. W., Tuder, R. M., Georas, S. N., and Biswal, S. (2005) Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 202, 47-59
13. Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S. S., Kensler, T. W., Yamamoto, M., Petrache, I., Tuder, R. M., and Biswal, S. (2004) Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Investig. 114, 1248-1259
14. Khor, T. O., Huang, M. T., Kwon, K. H., Chan, J. Y., Reddy, B. S., and Kong, A. N. (2006) Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res. 66, 11580-11584
15. Juge, N., and Mithen, R. F., and Traka, M. (2007) Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell. Mol. Life Sci. 64, 1105-1127
16. Li, Y., Zhang, T., Korkaya, H., Liu, S., Lee, H. F., Newman, B., Yu, Y., Clouthier, S. G., Schwartz, S. J., Wicha, M. S., and Sun, D. (2010) Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 16, 2580-2590
17. Aires, A., Mota, V. R., Saavedra, M. J., Rosa, E. A., and Bennett, R. N. (2009) The antimicrobial effects of glucosinolates and their respective enzymatic hydrolysis products on bacteria isolated from the human intestinal tract. J. Appl. Microbiol. 106, 2086-2095
18. Nallasamy, P., Si, H., Babu, P. V., Pan, D., Fu, Y., Brooke, E. A., Shah, H., Zhen, W., Zhu, H., Liu, D., Li, Y., and Jia, Z. (2014) Sulforaphane reduces vascular inflammation in mice and prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway. J. Nutr. Biochem. 25, 824-833
19. Nguyen, B., Luong, L., Naase, H., Vives, M., Jakaj, G., Finch, J., Boyle, J., Mulholland, J. W., Kwak, J. H., Pyo, S., de Luca, A., Athanasiou, T., Ange-lini, G., Anderson, J., Haskard, D. O., and Evans, P. C. (2014) Sulforaphane pretreatment prevents systemic inflammation and renal injury in response to cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 148, 690-697.e3
20. Sun, C., Yang, C., Xue, R., Li, S., Zhang, T., Pan, L., Ma, X., Wang, L., and Li, D. (2015) Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J. Appl. Physiol. 118, 224-237
21. Souza, C. G., Riboldi, B. P., Hansen, F., Moreira, J. D., Souza, D. G., de Assis, A. M., Brum, L. M., Perry, M. L., and Souza, D. O. (2013) Chronic sulforaphane oral treatment accentuates blood glucose impairment and may affect GLUT3 expression in the cerebral cortex and hypothalamus of rats fed with a highly palatable diet. Food Funct. 4, 1271-1276
22. de Souza, C. G., Sattler, J. A., de Assis, A. M., Rech, A., Perry, M. L., and Souza, D. O. (2012) Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. J. Med. Food 15, 795-801
23. Hori, Y. S., Kuno, A., Hosoda, R., Tanno, M., Miura, T., Shimamoto, K., and Horio, Y. (2011) Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. J. Pharmacol. Exp. Ther. 338, 784-794
24. Nakaso, K., Yano, H., Fukuhara, Y., Takeshima, T., Wada-Isoe, K., and Nakashima, K. (2003) PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett. 546, 181-184
25. Jørgensen, L. H., Blain, A., Greally, E., Laval, S. H., Blamire, A. M., Davison, B. J., Brinkmeier, H., MacGowan, G. A., Schrøder, H. D., Bushby, K., Straub, V., and Lochmüller, H. (2011) Long-term blocking of calcium channels in mdx mice results in differential effects on heart and skeletal muscle. Am. J. Pathol. 178, 273-283
26. Straub, V., Rafael, J. A., Chamberlain, J. S., and Campbell, K. P. (1997) Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 139, 375-385
27. Evans, N. P., Call, J. A., Bassaganya-Riera, J., Robertson, J. L., and Grange, R. W. (2010) Green tea extract decreases muscle pathology and NF-κB immunostaining in regenerating muscle fibers of mdx mice. Clin. Nutr. 29, 391-398
28. Charan, R. A., and Hanson, R., and Clemens, P. R. (2012) Deubiquitinating enzyme A20 negatively regulates NF-κB signaling in skeletal muscle in mdx mice. FASEB J. 26, 587-595
29. Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T., and Magyar, J. P. (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord. 14, 675-682
30. Davies, K. E., and Grounds, M. D. (2006) Treating muscular dystrophy with stem cells? Cell 127, 1304-1306
31. Trollet, C., Athanasopoulos, T., Popplewell, L., Malerba, A., and Dickson, G. (2009) Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin. Biol. Ther. 9, 849-866
32. Barton, E. R., Morris, L., Musaro, A., Rosenthal, N., and Sweeney, H. L. (2002) Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157, 137-148
33. Blaauw, B., Mammucari, C., Toniolo, L., Agatea, L., Abraham, R., Sandri, M., Reggiani, C., and Schiaffino, S. (2008) Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet. 17, 3686-3696
34. Bogdanovich, S., Krag, T. O., Barton, E. R., Morris, L. D., Whittemore, L. A., Ahima, R. S., and Khurana, T. S. (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420, 418-421
35. Heier, C. R., Damsker, J. M., Yu, Q., Dillingham, B. C., Huynh, T., Van der Meulen, J. H., Sali, A., Miller, B. K., Phadke, A., Scheffer, L., Quinn, J., Tatem, K., Jordan, S., Dadgar, S., Rodriguez, O. C., Albanese, C., Calhoun, M., Gordish-Dressman, H., Jaiswal, J. K., Connor, E. M., McCall, J. M., Hoffman, E. P., Reeves, E. K., and Nagaraju, K. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med. 5, 1569-1585
36. Bauer, R., Straub, V., Blain, A., Bushby, K., and MacGowan, G. A. (2009) Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur. J. Heart Fail. 11, 463-471
37. Granchelli, J. A., and Pollina, C., and Hudecki, M. S. (1995) Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity. J. Neurol. Sci. 131, 1-7
38. Nahirney, P. C., and Dow, P. R., and Ovalle, W. K. (1997) Quantitative morphology of mast cells in skeletal muscle of normal and genetically dystrophic mice. Anat. Rec. 247, 341-349
39. Gorospe, J. R., Tharp, M., Demitsu, T., and Hoffman, E. P. (1994) Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscul. Disord. 4, 325-333
40. Spencer, M. J., Walsh, C. M., Dorshkind, K. A., Rodriguez, E. M., and Tidball, J. G. (1997) Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Investig. 99, 2745-2751
41. Spencer, M. J., Montecino-Rodriguez, E., Dorshkind, K., and Tidball, J. G. (2001) Helper (CD4) and cytotoxic (CD8) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 98, 235-243
42. Anderson, J. E., and Ovalle, W. K., and Bressler, B. H. (1987) Electron microscopic and autoradiographic characterization of hindlimb muscle regeneration in the mdx mouse. Anat. Rec. 219, 243-257
43. Wehling, M., and Spencer, M. J., and Tidball, J. G. (2001) A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155, 123-131
44. Mao, L., Wang, H., Qiao, L., and Wang, X. (2010) Disruption of Nrf2 enhances the upregulation of nuclear factor-κB activity, tumor necrosis factor-α, and matrix metalloproteinase-9 after spinal cord injury in mice. Mediators Inflamm. 2010, 238321
45. Moon, D. O., Kim, M. O., Kang, S. H., Choi, Y. H., and Kim, G. Y. (2009) Sulforaphane suppresses TNF-α-mediated activation of NF-κB and induces apoptosis through activation of reactive oxygen species-dependent caspase-3. Cancer Lett. 274, 132-142
46. Durham, W. J., Arbogast, S., Gerken, E., Li, Y. P., and Reid, M. B. (2006) Progressive nuclear factor-κB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34, 298-303
47. Farkas, D., Alhussaini, A. A., Kraskauskas, D., Kraskauskiene, V., Cool, C. D., Nicolls, M. R., Natarajan, R., and Farkas, L. (2014) Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats. Am. J. Respir. Cell Mol. Biol. 51, 413-425
48. Price, L. C., Caramori, G., Perros, F., Meng, C., Gambaryan, N., Dorfmuller, P., Montani, D., Casolari, P., Zhu, J., Dimopoulos, K., Shao, D., Girerd, B., Mumby, S., Proudfoot, A., Griffiths, M., Papi, A., Humbert, M., Adcock, I. M., and Wort, S. J. (2013) Nuclear factor κ-B is activated in the pulmonary vessels of patients with end-stage idiopathic pulmonary arterial hypertension. PLoS One 8, e75415
49. Barnes, P. J., and Karin, M. (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066-1071
50. Scaife, C. L., Kuang, J., Wills, J. C., Trowbridge, D. B., Gray, P., Manning, B. M., Eichwald, E. J., Daynes, R. A., and Kuwada, S. K. (2002) Nuclear factor κB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 62, 6870-6878
51. Jin, W., Zhu, L., Guan, Q., Chen, G., Wang, Q. F., Yin, H. X., Hang, C. H., Shi, J. X., and Wang, H. D. (2008) Influence of Nrf2 genotype on pulmonary NF-κB activity and inflammatory response after traumatic brain injury. Ann. Clin. Lab. Sci. 38, 221-227
52. Jin, W., Wang, H., Yan, W., Zhu, L., Hu, Z., Ding, Y., and Tang, K. (2009) Role of Nrf2 in protection against traumatic brain injury in mice. J. Neurotrauma 26, 131-139